Stock A226950 OLIX PHARMACEUTICALS, INC
Add to a list
To use this feature you must be a member
Log inSign up

Other languages OliX Pharmaceuticals, Inc

Equities

A226950

KR7226950004

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 29/04/2024 BST 		5-day change 1st Jan Change
15,670 KRW +1.10% Intraday chart for OliX Pharmaceuticals, Inc +2.82% +7.48%
03-22 OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors CI
03-20 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 14.7 billion in funding from a group of investors CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
OliX Pharmaceuticals, Inc Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug
OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration
OliX Pharmaceuticals, Inc. Announces First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia
OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2023
OliX Pharmaceuticals, Inc. Presents Preclinical Data Showing Synergistic Weight Loss from Anti-NASH siRNA and Semaglutide Combination Treatment
OliX Pharmaceuticals, Inc Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA At Korea-US Digital BioHealth Business Forum
OliX Pharmaceuticals, Inc Announces Positive Results from A Phase 2A Trial of Olx10010 for Hypertrophic Scar Treatment
Olix Pharmaceuticals, Inc. Doses First Patient in Clinical Trial for Rnai Therapeutic Olx10212 for Dry and Wet Age-Related Macular Degeneration
OliX Pharmaceuticals, Inc. Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia
PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd.
Olix Pharmaceuticals Publishes Preclinical Research Demonstrating Olx104c’S Potential as an Effective Treatment for Hair Loss
OliX Pharmaceuticals, Inc Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-Related Macular Degeneration
OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial
Olix Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of Olx101a in Patients with Hypertrophic Scars
Olix Pharmaceuticals,Inc Identifies Effective Inhibition of Target Gene Expression and Delivery of Candidate to Brain for CNS Therapeutics
OliX Pharmaceuticals,Inc Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A226950 Stock
  4. News OliX Pharmaceuticals, Inc
  5. Other languages